Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA): A Phase 4 Double-Blinded, Parallel-Group, Randomized Control Trial With an Open Label Extension

NCT06705764 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT06705764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA): A Phase 4 Double-Blinded, Parallel-Group, Randomized Control Trial With an Open Label Extension
Lead sponsor
University of Alberta
Phase
Phase 4
Overall status
Recruiting
Start date
May 11, 2026
Completion date
November 30, 2026
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma